日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

丙型肝炎治疗的新范式:将口服疗法纳入最佳实践

Afdhal, N H; Zeuzem, S; Schooley, R T; Thomas, D L; Ward, J W; Litwin, A H; Razavi, H; Castera, L; Poynard, T; Muir, A; Mehta, S H; Dee, L; Graham, C; Church, D R; Talal, A H; Sulkowski, M S; Jacobson, I M

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

需要建立细胞因子、趋化因子和免疫激活血浆标志物的外部能力验证计划

Fahey J L, Aziz N, Spritzler J, Plaeger S, Nishanian P, Lathey J L, Seigel J, Landay A L, Kilarui R, Schmitz J L, White C, Wara D W, Akridge R, Cutili J, Douglas S D, Reuben J, Shearer W T, Nokta M, Polland R, Schooley R, Asthana D, Mizrachi Y, Waxdal M

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39

负责抑制血小板功能的内皮细胞外ADP酶是CD39。

A J Marcus ,M J Broekman, J H Drosopoulos, N Islam, T N Alyonycheva, L B Safier, K A Hajjar, D N Posnett, M A Schoenborn, K A Schooley, R B Gayle, C R Maliszewski

Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon alpha

干扰素α预防Epstein-Barr病毒诱导的B细胞过度增殖

Garner, J G; Hirsch, M S; Schooley, R T